10.14.11
Oncobiologics has signed an agreement with Parilis Biopharmaceuticals involving worldwide licensing for an undisclosed biotherapeutic product, and another agreement with a U.S.-based large pharmaceutical company to conduct research on solving issues related to downstream processing of monoclonal antibodies. The combined value of these agreements total approximately $80 million.
Dennis O'Donnell, chief executive officer of Parilis Biopharmaceuticals, said, "This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics' capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success."
Oncobiologics vice president of business development, Jeremy Caudill, added, "These programs represent a significant milestone for Oncobiologics. They are a validation of our dual strategies, as both a fully integrated biopharmaceutical company, and a provider of world-class proof-of-concept services to customers and partners."
Dennis O'Donnell, chief executive officer of Parilis Biopharmaceuticals, said, "This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics' capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success."
Oncobiologics vice president of business development, Jeremy Caudill, added, "These programs represent a significant milestone for Oncobiologics. They are a validation of our dual strategies, as both a fully integrated biopharmaceutical company, and a provider of world-class proof-of-concept services to customers and partners."